Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen

Pediatric Dermatology

Volumn 26, Issue 1, 2009, Pages 23-27

  Borska, Lenka ^a,b   Andrys, Ctirad ^b   Krejsek, Jan ^b   Hamakova, Kvetoslava ^b   Kremlacek, Jan ^b   Ettler, Karel ^b   Vellappally, Sajith ^b   Vimal, Jacob ^b   Fiala, Zdenek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COAL TAR; HEAT SHOCK PROTEIN 70; POLYCYCLIC AROMATIC HYDROCARBON;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CELL STRESS; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DISEASE SEVERITY; EXPOSURE; FEMALE; GENOTOXICITY; HEAT SHOCK; HUMAN; LOCAL THERAPY; MALE; PEDIATRICS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PSORIASIS; SCHOOL CHILD; SHOCK; ULTRAVIOLET IRRADIATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHROMOSOME ABERRATIONS; COAL TAR; COMBINED MODALITY THERAPY; CZECH REPUBLIC; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KERATOLYTIC AGENTS; LYMPHOCYTES; MALE; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STRESS, PHYSIOLOGICAL; ULTRAVIOLET RAYS;

EID: 60449118932     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2008.00774.x     Document Type: Article

References (28)

1. Thami GP, Sarkar R. Coal tar: past, present and future. Clin Exp Dermatol 2002 27 : 99 103.
2. Borska L, Fiala Z, Krejsek J et al. Cytogenetic and immunological changes after dermal exposure to polycyclic aromatic hydrocarbons and UV radiation. Physiol Res 2006 55 : 317 323a.
3. Borska L, Fiala Z, Krejsek J et al. Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006 55 : 699 706b.
4. Fiala Z, Borska L, Pastorkova A et al. Genotoxic effect of Goeckerman regimen of psoriasis. Arch Dermatol Res 2006 298 : 243 251.
5. Lee E, Koo J. Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatolog Treat 2005 16 : 102 107.
6. Feldman SR. Where has Goeckerman treatment gone? J Dermatolog Treat 2005 16 : 73 74.
7. IARC. Monographs on the evaluation carcinogenic risk of chemicals to humans; polynuclear aromatic compounds, The International Agency for Research on Cancer. Lyon, France : World Health Organisation, 1998.
8. Zanoli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003 49 : 78 86.
9. Van de Kerkhof PC, Vissers WH. Established treatment of psoriasis. Curr Drug Targets Inflamm Allergy 2004 3 : 45 156.
10. Borska L, Fiala Z, Smejkalova J et al. Genotoxic risk of Goeckerman's therapy of psoriasis. Pilot study-children (in Czech). Acta Medica (Hradec Kralove) Suppl 2004 47 : 19 21.
11. Borska L, Fiala Z, Krejsek J et al. Immunological changes in TNF-alpha, sEselectin, sP-selectin, sICAM-1 and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol 2007 24 : 607 612.
12. de Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2004 17 : 341 349.
13. AHEM. Standardized operating approaches for biological monitoring of genotoxic effects of environmental factors. AHEM 3/2003. Praha : National Institute of Health, 2003.
14. Janniger CK, Schwartz RA, Musumeci ML et al. Infantile psoriasis. Cutis 2005 76 : 173 177.
15. Boffetta P, Gridley G, Lindelö B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001 117 : 1531 1537.
16. Hannuksela-Svahn A, Pukkala E, Läärä E et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000 114 : 587 590.
17. Boffetta P, van der Hel O, Norppa H et al. Chromosomal aberrations and cancer risk: results of a cohort study from Central Europe. Am J Epidemiol 2007 165 : 36 43.
18. Rossner P, Boffetta P, Ceppi M et al. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environ Health Perspect 2005 113 : 517 520.
19. Merlo DF, Ceppi M, Stagei E et al. Baseline chromosome aberrations in children. Toxicol Lett 2007 172 : 60 67.
20. Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol 2002 92 : 2177 2186.
21. Aufricht C. HSP: helper, suppressor, protector. Kidney Int 2004 65 : 739 740.
22. Soti C, Csarmely P. Aging and molecular chaperones. Exp Gerontol 2003 38 : 1037 1040.
23. Arrigo AP. [Heat shock proteins as molecular chaperones]. Med Sci (Paris) 2005 21 : 619 625.
24. Soti C, Nagy E, Giricz Z et al. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005 146 (6 769 780.
25. Cruz-Rodriguez LA, Chu FL. Heat-shock protein (HSP70) response in the eastern oyster, Crassostrea virginica, exposed to PAHs sorbed to suspended artificial clay particles and to suspended field contaminated sediments. Aquat Toxicol 2002 60 : 157 168.
26. Weber LP. Acute ex vivo effects of dimethylbenz[a]anthracene and heat shock on rat tail artery. Cardiovasc Toxicol 2004 4 : 355 362.
27. Trautinger F. Heat shock proteins in the photobiology of human skin. J Photochem Photobiol B 2001 63 : 70 77.
28. Merwald H, Kokesch C, Klosner G et al. Induction of the 72-kilodalton head shock protein and protection from ultraviolet B-induced cell death in human keratinocytes by repetitive exposure to heat shock or 15-deoxy-delta (12,14)-prostaglandin J2. Cell Stress Chaperones 2006 11 : 81 88.